Zacks Investment Research upgraded shares of Genocea Biosciences (NASDAQ:GNCA) from a hold rating to a buy rating in a report issued on Monday morning. The brokerage currently has $0.75 target price on the biotechnology company’s stock.
According to Zacks, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. “
Separately, HC Wainwright reiterated a buy rating and set a $5.00 price objective on shares of Genocea Biosciences in a research note on Thursday, November 1st. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Genocea Biosciences currently has a consensus rating of Buy and an average target price of $3.35.
Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. As a group, equities analysts expect that Genocea Biosciences will post -0.45 EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in GNCA. California State Teachers Retirement System raised its stake in shares of Genocea Biosciences by 166.6% during the 1st quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 78,469 shares during the period. LMR Partners LLP bought a new stake in shares of Genocea Biosciences during the 2nd quarter valued at $175,000. Schwab Charles Investment Management Inc. bought a new stake in shares of Genocea Biosciences during the 1st quarter valued at $177,000. DRW Securities LLC bought a new stake in shares of Genocea Biosciences during the 2nd quarter valued at $205,000. Finally, Paloma Partners Management Co bought a new stake in shares of Genocea Biosciences during the 2nd quarter valued at $343,000. Institutional investors own 60.23% of the company’s stock.
About Genocea Biosciences
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.
Recommended Story: What is Cost of Debt?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.